BI-144807
/ Boehringer Ingelheim
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 11, 2022
Safety and therapeutic effects of orally administered AKST4290 in newly diagnosed neovascular age-related macular degeneration.
(PubMed, Retina)
- "To evaluate the safety and therapeutic effects of orally administered AKST4290 (formerly BI 144807 and ALK4290) in treatment-naive patients with neovascular age-related macular degeneration (nAMD). All adverse events (AEs) were mild or moderate in severity and no safety issues were identified. Treatment of nAMD with AKST4290 warrants further investigation in randomized, placebo-controlled trials."
Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
1 to 1
Of
1
Go to page
1